Quidel Corporation (NASDAQ:QDEL) CEO Douglas C. Bryant sold 12,000 shares of Quidel Corporation stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $41.15, for a total transaction of $493,800.00. Following the sale, the chief executive officer now owns 296,493 shares of the company’s stock, valued at $12,200,686.95. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of Quidel Corporation (QDEL) traded down 0.27% on Tuesday, hitting $40.95. The company had a trading volume of 309,086 shares. The company has a 50-day moving average of $41.83 and a 200 day moving average of $32.20. Quidel Corporation has a 12 month low of $18.25 and a 12 month high of $45.55. The stock’s market cap is $1.37 billion.

TRADEMARK VIOLATION WARNING: “Douglas C. Bryant Sells 12,000 Shares of Quidel Corporation (QDEL) Stock” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/31/douglas-c-bryant-sells-12000-shares-of-quidel-corporation-qdel-stock.html.

A number of large investors have recently bought and sold shares of the stock. Legal & General Group Plc grew its stake in Quidel Corporation by 4.0% in the 2nd quarter. Legal & General Group Plc now owns 7,209 shares of the company’s stock valued at $197,000 after buying an additional 278 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in Quidel Corporation by 1.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,831 shares of the company’s stock valued at $593,000 after buying an additional 333 shares during the last quarter. AHL Partners LLP grew its stake in Quidel Corporation by 4.0% in the 2nd quarter. AHL Partners LLP now owns 18,666 shares of the company’s stock valued at $507,000 after buying an additional 718 shares during the last quarter. TIAA CREF Investment Management LLC grew its stake in Quidel Corporation by 1.1% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 99,227 shares of the company’s stock valued at $2,693,000 after buying an additional 1,062 shares during the last quarter. Finally, Acrospire Investment Management LLC grew its stake in Quidel Corporation by 42.2% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,678 shares of the company’s stock valued at $100,000 after buying an additional 1,091 shares during the last quarter. Institutional investors and hedge funds own 86.92% of the company’s stock.

QDEL has been the subject of a number of research reports. TheStreet upgraded shares of Quidel Corporation from a “c+” rating to a “b-” rating in a research report on Thursday, July 6th. Raymond James Financial, Inc. restated a “buy” rating and set a $47.00 price objective (up from $41.00) on shares of Quidel Corporation in a research report on Tuesday, September 19th. Canaccord Genuity upgraded Quidel Corporation from a “hold” rating to a “buy” rating in a research report on Tuesday, July 18th. Zacks Investment Research upgraded Quidel Corporation from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a research report on Tuesday, July 18th. Finally, BidaskClub downgraded Quidel Corporation from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 16th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $48.00.

About Quidel Corporation

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.

Insider Buying and Selling by Quarter for Quidel Corporation (NASDAQ:QDEL)

Receive News & Ratings for Quidel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.